ADAPT-Sepsis (@adaptsepsis) 's Twitter Profile
ADAPT-Sepsis

@adaptsepsis

Biomarker-guided duration of antibiotic treatment for sepsis

ID: 1066295928116703232

linkhttps://warwick.ac.uk/fac/sci/med/research/ctu/trials/adaptsepsis/ calendar_today24-11-2018 11:42:14

679 Tweet

860 Followers

905 Following

Oldham ICU (@oldhamicu) 's Twitter Profile Photo

Great work to all involved in completing recruitment to the ADAPT-Sepsis study. Thank you to our research team for their hard work in recruiting 85 of the number below! NCA Research NHS Oldham Care Organisation

CEDAR (@cedar_cardiff) 's Twitter Profile Photo

Thrilled to hear that the ADAPT-Sepsis team have reached their recruitment target - well done everyone! We're looking forward to comparing our process evaluation findings with your trial results in the coming months! cedar.nhs.wales/our-work/clini…

Critical Care Reviews (@critcarereviews) 's Twitter Profile Photo

We're delighted to announce ADAPT-Sepsis as our first trial result presentation at #CCRdownunder ADAPT-Sepsis is a 2760 patient RCT investigating biomarker-guided duration of antibiotic therapy in patients with sepsis To be presented by Paul Dark criticalcarereviews.com/meetings/ccr-d…

We're delighted to announce <a href="/AdaptSepsis/">ADAPT-Sepsis</a> as our first trial result presentation at #CCRdownunder

ADAPT-Sepsis is a 2760 patient RCT investigating biomarker-guided duration of antibiotic therapy in patients with sepsis

To be presented by <a href="/DarkNatter/">Paul Dark</a> 

criticalcarereviews.com/meetings/ccr-d…
Keith Couper (@keithcouper) 's Twitter Profile Photo

Fantastic work led by Paul Dark and delivered by the phenomenal UK Critical Care community. We can safely reduce antibiotic duration using procalcitonin (but not CRP). ADAPT-Sepsis Warwick CTU

Oldham ICU (@oldhamicu) 's Twitter Profile Photo

We are delighted to have contributed to this important trial. Because clinical research is how we improve the care we deliver. Thank you to our patients who took part. ADAPT-Sepsis NCA Research NHS Paul Dark

The University of Manchester News (@uomnews) 's Twitter Profile Photo

A major UK patient trial of a new biomarker testing protocol for sepsis, led by The University of Manchester researchers, has shown it is possible to safely stop antibiotic treatment earlier than current care 🔬 UoM Biology, Medicine and Health Paul Dark Read more about the trial 👇 manchester.ac.uk/about/news/bio…

Enitan Carrol 🇬🇲🇸🇱🏴󠁧󠁢󠁳󠁣󠁴󠁿🇬🇧 (@carrolenitan) 's Twitter Profile Photo

1/ Delighted to report the results of the Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH) trial in The Lancet Child & Adolescent Health thelancet.com/journals/lanch…

Paul Dark (@darknatter) 's Twitter Profile Photo

The Bottom Line hrishee Thank you for this detailed review and comments. We ADAPT-Sepsis are working on trial process evaluation and health economic outcomes right now, so more to come to aid understanding of results. Hopefully, we will see you all Intensive Care Society 💙 events in 2025 for further discussions

JAMA (@jama_current) 's Twitter Profile Photo

Editor’s choice from the February 25 issue. ➡️ Camrelizumab With Chemotherapy in Patients With Early or Locally Advanced TNBC ➡️ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis ➡️ Essential Thrombocythemia: A Review; and more.

Editor’s choice from the February 25 issue.

➡️ Camrelizumab With Chemotherapy in Patients With Early or Locally Advanced TNBC 
➡️ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
➡️ Essential Thrombocythemia: A Review; and more.